Hi MJ, I could well be wrong, but I don't remem

Quote:

---

]I'm also pleased to confirm, that CytoDyn is collaborating on an exploratory investigator-initiated pilot study of leronlimab in patients with Alzheimer's disease. Cytodyn is fortunate to be working on this project with a highly experienced investigator and a leading academic Medical Center. The study proposes to enroll 20 patients, with mild to moderate Alzheimer's disease, who are treated with leronlimab at either 350 or 700 milligrams weekly and followed for 12 weeks with a primary neuro-radiology endpoint.

I look forward to providing additional details on future calls, but it's important to note that we have already identified an external source of funding for this study.

---